DYN Q4 2022 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$40M

Net Income

-$39M

EPS (Diluted)

$-0.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$306M

Total Liabilities

$54M

Stockholders' Equity

$252M

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$40M	-$52M	+22.7%
Net Income	-$39M	-$52M	+25.0%